RAS Among First in the Nation to offer PROVENGE®
New immunotherapy treatment method now available at
Sacramento Clinic for Hematology and Medical Oncology Center
For Immediate Release (Sacramento, Calif., July 7, 2011) – RAS’ Clinic for Hematology and Medical Oncology, commonly referred to as SCHMO, is the first provider in Northern California, and among the first sites in the nation to treat advanced prostate cancer patients with PROVENGE® (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies. PROVENGE® was approved by the U.S. Food and Drug Administration (FDA) for the treatment of men with asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone refractory) prostate cancer and is made by Dendreon Corporation.
PROVENGE® is an autologous cellular immunotherapy designed to stimulate a patient’s immune system to identify and target prostate cancer cells. Each dose is manufactured specifically for each patient using his own immune cells. The cells are activated with a recombinant antigen that seeks out and attacks prostate cancer cells. Studies have shown that PROVENGE® extended median survival to 25.8 months compared to 21.7 to a control group of patients.
According to Samer Shihabi, M.D., RAS Medical Oncologist, “PROVENGE® offers men with metastatic disease an opportunity to extend their lives with minimal side effects.” Adding “Because the procedure has been approved by Medicare this advanced treatment can be considered a viable alternative.” Dendreon Corporation offers additional financial assistance to those who are eligible.
PROVENGE® is indicated for men with metastatic castrate-resistant prostate cancer (CRPC) and asymptomatic or minimally symptomatic disease. Additional criteria for consideration include no visceral metastases (lung, liver or brain), no treatment with chemotherapy in at least the previous three months and no treatment with 28 days with systemic corticosteroids.
The most common side effects associated with PROVENGE® are primarily mild or moderate chills, fatigue, fever, back pain, nausea, joint ache and headache. In controlled clinical trials, serious adverse events reported in the Sipuleucel-T Immunotherapy group included acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. Severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in this group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the study group.
Individuals interested in learning whether PROVENGE® is an appropriate treatment option should contact RAS at (916) 374-5500 or call 1-877-336-3736. To learn more visit www.PROVENGE.com.
About Radiological Associates of Sacramento
Radiological Associates of Sacramento (RAS) Medical Group, Inc. (www.radiological.com) is a premier provider of specialty healthcare services in Northern California. Its core services include diagnostic radiology, interventional and neurointerventional radiology, radiation oncology, nuclear medicine, gynecologic oncology, urology, vascular surgery, and hematology/medical oncology. RAS provides quality care to patients through its multiple outpatient clinics.
# # #
Contact: Kelly Balaam, Associate Director, Marketing |
Contact Phone Number: 916 797-6456
Contact Fax Number: 916 564-3508
Contact Email: BalaamK@radiological.com
Publication Date: July 7, 2011